drugset / Trial / NCT00057356

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

NCT00057356

Phase 2 Completed 170 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.

Timeline

Start
2002-11
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Conivaptan Small molecule

Indications